FierceBiotech

AbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition

After debunking earlier rumors that it was acquiring RAS superstar Revolution Medicines, AbbVie is now taking a more definitive step into the red-hot cancer field. The Chicago pharma has agreed to ...
Seeking Alpha

Erasca, Inc. (ERAS) Discusses Preliminary Phase I Data and Differentiation of Pan-RAS Molecular Glue ERAS-0015 Transcript

Greetings, and welcome to the Erasca Corporate Update Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Jonathan Lim, CEO and Chairman.
Business Insider

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L KRAS ...
Mena FN

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data For Potentially Best-In-Class Pan-RAS Molecular Glue ERAS-0015 In KRAS-Mutant Solid Tumors

(MENAFN- GlobeNewsWire - Nasdaq) Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE ...
CNN

Tired of high costs, some Americans are importing homes straight from China

Gennadiy Tsygan knows how expensive it is to build a home in the United States. That’s why he imported almost everything for his dream house from China. Most of his home fixtures were imported ...
FierceBiotech

AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...
Business Insider

Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...
GEN

Landmark Pancreatic Cancer Trial Highlights Promise of RAS-Targeting Daraxonrasib

Earlier this week, Revolution Medicines reported positive results from a global Phase III trial of its RAS‑targeting inhibitor daraxonrasib (RMC-6236) in metastatic pancreatic ductal adenocarcinoma ...
Reuters

US import prices increase below expectations; sharp rise anticipated due to Iran war

WASHINGTON, April 15 (Reuters) - U.S. import prices increased less than expected in March, though the trend still pointed to firming imported inflationary pressures as the Middle East conflict boosts ...
SciELO

APPLICABILITY OF HEC-DSSVue FOR MANAGEMENT OF HYDROLOGICAL GAGING NETWORK: A CASE STUDY USING SUB-HOURLY RAINFALL DATASETS FROM SOUTHERN BRAZIL

Hydrological data are typically sequential and often correspond to large datasets, and not all application programs allow their retrieval, storage, and manipulation. This technical article aims to ...
csis.org

Reining in the Export Control Arms Race

Export controls are a critical instrument of U.S. national security policy, designed to prevent adversaries from acquiring technologies that could enhance military capabilities or undermine global ...
Engadget

Google Gemini now lets you import your chats and data from other AI apps

Google is adding a pair of new features to Gemini aimed at making it easier to switch to the AI chatbot. Personal history and past context are big components to how a chatbot provides customized ...